Avastin is non-toxic

Article

Avastin (bevacizumab) does not exert any toxic effects on the retina and its function, according to a study published in the January issue of Retina journal.

Avastin (bevacizumab) does not exert any toxic effects on the retina and its function, according to a study published in the January issue of Retina journal.

A team led by Professor Peter Heidushka of the University Eye Hospital Tuebingen, Tuebingen, Germany, examined the retinal function of wild-type mice that received an intravitreal injection of Avastin.

Electroretinography (ERG) was performed on four different groups of mice: group 1) mice were injected intravitreally with BSS; group 2) mice received injections of a vehicle solution; group 3) mice were injected with Avastin solution; group 4) mice received sham surgery. ERG was performed before treatment and one, four, 12, and 25 days post treatment.

ERG parameters were similar in all four groups; no difference could be seen between eyes injected with Avastin and those receiving the vehicle solution. Bevacizumab immunoreactivity was present in the retina 30 mins after Avastin injection, but this was no longer detectable 25 days later.

The authors therefore concluded that Avastin does not have any harmful effects on the retina or its function; it penetrates the retina quickly and safely after injection.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.